RenaSci, a Sygnature Discovery company, offers an integrated blend of consultancy and preclinical experimental services to the pharmaceutical industry. Our clients include pharma, biotech, virtual companies, and healthcare investors worldwide.
We focus on six key areas: abuse and dependence, CNS, obesity, diabetes, NASH and kidney disease.
Our regulatory expertise, combined with skills in drug development and abuse liability assessments, have been pivotal to the success of clients in achieving European and US drug registrations. We have facilitated more than 30 NCE’s into clinical development and 10 drugs to the market. The long term relationships we enjoy with many of our clients is testament to the quality of our service.
We focus on six key areas: abuse and dependence, CNS, obesity, diabetes, NASH and kidney disease.
Our regulatory expertise, combined with skills in drug development and abuse liability assessments, have been pivotal to the success of clients in achieving European and US drug registrations. We have facilitated more than 30 NCE’s into clinical development and 10 drugs to the market. The long term relationships we enjoy with many of our clients is testament to the quality of our service.
Employees: 11-50
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | BioCity | biocity.co... |
Mentions in press and media 1
| Date | Title | Description |
| 04.06.2020 | Sygnature acquires Alderley Oncology | Sygnature Discovery has further strengthened its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, which undertakes high quality research services for cancer drug discovery. |